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Background: Due to a limited number and disparate distribution of pediatric rheumatologists in the US, a variety
of physician types provide care to children with rheumatologic diseases. However, little is known about how that
care may differ across prescribing physician groups. Our objective was to compare medication claims for children
with juvenile idiopathic arthritis (JIA) by type of prescribing physician.
Methods: We performed a retrospective cohort study of children with JIA using Michigan Medicaid data for
7/1/2005-6/30/2007, employing descriptive and bivariate analyses by age, medication type, and prescriber type.
Results: Among 397 children, there was no difference in the frequency of medication claims for children with
internist versus pediatric rheumatologist prescribers. Children with non-rheumatologist prescribers were less likely
to have claims for disease modifying anti-rheumatic drugs (DMARDs) and biologic agents.
Conclusion: Differential use of DMARDs and biologic agents by rheumatologists indicates the importance of
referring children with JIA for specialty care.
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Previous studies have indicated that in many areas of
the United States, children do not have easy access to a
pediatric rheumatologist, due to both the small absolute
number of pediatric rheumatologists and their concen-
tration in academic centers [1-3]. Internist rheumatolo-
gists – who are more numerous and more geographically
dispersed than their pediatric colleagues – may therefore
play a prominent role in the care of children with rheu-
matologic conditions [4-6]. Some children may receive
care from primary care physicians or non-rheumatology
specialists for their rheumatologic disease [7]. The variety
of physician types providing care to children with rheu-
matologic diseases is of special concern to primary care
physicians, who must determine when and where to refer
their patients with rheumatologic complaints. Concerns
about specialist availability are particularly salient in states* Correspondence: mriebsch@med.umich.edu
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article, unless otherwise stated.such as Michigan, which has large rural areas, and numer-
ous medically underserved areas (MUAs) and health
professional shortage areas (HPSAs) in both urban and
rural settings.
Juvenile idiopathic arthritis (JIA) is the most common of
the pediatric rheumatologic conditions, with a prevalence
of approximately 60 cases per 100,000 children [8]. Studies
have indicated that time-to-treatment with DMARDs or
biologic agents is an important factor in response to
these drugs for children with JIA [9,10]. Although several
studies have addressed the participation of internist rheu-
matologists and primary care physicians in the care of
children with JIA [4-7], it is unclear whether children with
JIA receive different medications, depending upon their
prescribing physician type. As such, primary care physi-
cians, policy makers, and parents are missing a critical
piece of information as they decide where to send children
with possible JIA. The goal of this study was to explore
prescription patterns for medications commonly used to
treat JIA based upon prescriber type.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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This study was approved by the University of Michigan
Medical School Institutional Review Board. Administra-
tive claims data were obtained from Michigan Medicaid
for 7/1/2005-6/30/2007. The study population was limited
to children 21 years of age or younger, with Medicaid
enrollment for ≥11 months in at least one study year, and
with no other insurance coverage. A sensitivity analysis
including only those children 15 years of age or younger
was also performed.
To minimize misclassification, children were defined
as having JIA if they had at least 1 claim for a medication
commonly used to treat JIA, and at least 1 visit coded for
a JIA diagnosis (ICD-9-CM 714.30, 714.31, 714.32, 714.33,
714.0, 696.0, 720.0, 720.89). Lab and radiology tests were
not considered visits. Children with ICD-9-CM codes
for other rheumatic diseases (710.xx) were excluded, as
those diseases may include arthritis but would supersede a
diagnosis of JIA.
Demographic information included age and race.
Pharmacy claims included National Drug Codes and
prescriber identification numbers. Medications com-
monly used to treat JIA included non-steroidal anti-794,892 children enrolled in 
Medicaid for at least 11/12 
months for at least 1 year (7/1/05-
6/30/06 or 7/1/06-6/30/07), and 
with no other insurance coverage 
during that year
573 children with at least 
one visit coded with a JIA 
ICD-9-CM code during the 
study period
540 children with possible 
JIA
397 children included in 
study cohort
Figure 1 Cohort diagram.inflammatory drugs (NSAIDs), disease modifying anti-
rheumatic drugs (DMARDs), biologic agents, and any
other medication prescribed by a rheumatologist. Using
prescriber identification numbers linked to Medicaid
provider specialty data, prescribers were classified as
pediatric rheumatologists, internist rheumatologists, non-
rheumatology specialists (which included all physicians
who were neither rheumatologists nor primary care
physicians), primary care physicians (which included
general pediatricians, family practitioners, and general
internists), or hospital/unknown. To verify the accuracy
of this classification, one author (HvM) reviewed the
list of prescribing physicians by hand. Children with
multiple prescriber types were placed in the group of
the most specialized prescriber, as that physician was
presumed to be directing the overall care. Children
whose prescribers were only in the hospital/unknown
group were excluded from analyses investigating pre-
scribing patterns.
Descriptive analyses included counts and proportions.
Chi square tests were used for bivariate analyses. P
values <0.05 were considered statistically significant.
Analyses were performed using STATA version 10.Excluded: 
- 33 children with ICD-9-
CM codes for other 
rheumatic conditions
Excluded: 
- 143 children with no JIA 
medications
Table 1 Demographic characteristics of prescriber groups
Pediatric rheumatologist
prescriber (N = 188)
Internist rheumatologist
prescriber (N = 57)
Non-rheumatology specialist




0-5 years 27 (14%) 3 (5%) 0 (0%) 6 (15%)
6-10 years 43 (23%) 10 (18%) 2 (7%) 4 (10%)
11-15 years 76 (40%) 11 (19%) 7 (26%) 19 (46%)
16-21 years 42 (22%) 33 (58%) 18 (67%) 12 (29%)
Race
Caucasian 109 (58%) 43 (75%) 15 (56%) 28 (68%)
African American 66 (35%) 8 (14%) 10 (37%) 10 (24%)
Other/unknown 13 (7%) 6 (11%) 2 (7%) 3 (7%)
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Figure 1 shows the application of eligibility criteria,
which yielded a study population of 397 children. Of
those, 61% were Caucasian and 30% were African
American; 12% were 0–5 years of age, 19% were 6–11
years of age, 36% were 11–15 years of age, and 34% were
16–21 years of age.
By definition, all children in the cohort had a medication
claim, but 84 children (21%) had prescriptions only from
prescribers in the hospital/unknown group. Among the
remaining 313 children, 188 (47% of the cohort) had at
least one prescription written by a pediatric rheuma-
tologist, 57 (14%) had at least one prescription written
by an internist rheumatologist, 27 (7%) had at least one
JIA prescription from a non-rheumatology specialist but
none from a rheumatologist, and 41 children (10%) had
prescriptions only from primary care providers. There was
no significant difference between groups in the distributionFigure 2 Frequency of claims for JIA medication classes for children in e
and pediatric rheumatologist groups were more likely to have claims for DMAR
difference in the frequency of claims for any medication class when children inof races. Conversely, the population of children in the
pediatric rheumatologist group was significantly younger
than that in the internist rheumatologist group (p < .001)
(Table 1).
While 94% of the children in the cohort had a claim for
an NSAID filed during the study period, only 45% had a
claim for a DMARD and 17% had a claim for a biologic
agent. There was no significant difference between internist
and pediatric rheumatologist prescribers in the frequency
of claims for NSAIDs, DMARDs, or biologic agents; how-
ever, primary care physicians and non-rheumatology
specialists were significantly less likely than rheumatol-
ogists to prescribe DMARDs (p < .001) or biologic agents
(p < .001) (Figure 2). Separate analyses comparing internist
and pediatric rheumatologist prescribers within age
groups revealed no significant differences. The sensitivity
analysis including only children 15 years of age or younger
revealed the same pattern of findings.ach of the prescriber groups. Children in the internist rheumatologist
Ds (p < .001) or biologic agents (p < .001). There was no significant
the internist and pediatric rheumatologist groups were compared.
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In this study of Medicaid-enrolled children with JIA, the
prescribing patterns of internist rheumatologists did not
differ significantly from those of pediatric rheumatologists,
despite the differences in their patient populations. The
internist rheumatologist group included a higher propor-
tion of older children, consistent with prior studies [4-6]. It
is likely that internist rheumatologists are “self-selecting” a
patient population similar to the young adults already in
their practice; in contrast, internist rheumatologists may be
hesitant to take on the challenge of younger patients, who
may require different approaches to the physical exam and
different dosing regimens for medications.
The finding that the prescribing patterns of internist
rheumatologists were not significantly different from those
of pediatric rheumatologists, is contrary to the direction of
previous studies of pediatric versus adult primary care
providers [11,12]. The shared specialty-specific know-
ledge regarding rheumatology medications may ameliorate
differences in prescribing patterns between internist and
pediatric rheumatologists. It is also plausible that differ-
ences in prescribing patterns exist between internist
and pediatric rheumatologists, but that they pertain to
choice of specific agents and dosing regimens, rather
than frequency of use for medication types.
Primary care providers and non-rheumatology specialists
exclusively provided prescriptions for 17% of the cohort,
and these children were less likely to be prescribed
DMARDs and biologic agents. It would be appropriate for
primary care providers and non-rheumatology specialists
to limit their care to children who did not require more
aggressive medications; however, as a claims analysis, this
study did not have sufficient clinical information to deter-
mine whether this was the case.
This study is subject to several limitations. Although
the study yielded a disease prevalence of 50 JIA cases
per 100,000 children, consistent with previous studies
[8], the overall number of children in each prescriber group
was relatively small and limited the study’s statistical power.
In addition, although steps were taken to minimize the risk
of incorrect diagnosis, this study is subject to the possibility
of miscoding. Prescriptions outside the study period and
telephone consultations were not included, and thus we
could have underestimated the involvement of specialized
prescribers. We assumed that the most specialized pre-
scriber would be directing a patient’s care, but that may not
be accurate in all cases. Finally, these data are from 7/1/
2005-6/30/2007, and it is possible that prescribing patterns
may have changed since that time.
Conclusions
Despite the limitations, these findings have implications
for physicians who care for children with JIA. Although
the patient populations cared for by pediatric and internistrheumatologists were different, the prescribing patterns
for the two groups of providers were similar. Non-
rheumatology specialists and primary care providers, on
the other hand, were less likely to prescribe DMARDs
or biologic agents. Given that early treatment with these
agents has been associated with an improved likelihood
of response [9,10], primary care providers and non-
rheumatology specialists should consider early referral
to, or consultation with, a rheumatologist to ensure that
their pediatric patients with JIA are receiving appropriate
medications.
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